ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 297 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $60,234,561 | +50.0% | 1,485,073 | +22.3% | 0.02% | +36.4% |
| Q3 2022 | $40,148,578 | -2.8% | 1,214,783 | +3.5% | 0.01% | 0.0% |
| Q2 2022 | $41,307,421 | -4.6% | 1,173,173 | +24.7% | 0.01% | +22.2% |
| Q1 2022 | $43,279,763 | -5.5% | 941,069 | +36.2% | 0.01% | 0.0% |
| Q4 2021 | $45,802,000 | +8.6% | 690,823 | +2.2% | 0.01% | 0.0% |
| Q3 2021 | $42,194,000 | -26.7% | 675,857 | -2.7% | 0.01% | -25.0% |
| Q2 2021 | $57,557,000 | +21.1% | 694,960 | -3.0% | 0.01% | +9.1% |
| Q1 2021 | $47,519,000 | -27.9% | 716,613 | -16.6% | 0.01% | -26.7% |
| Q4 2020 | $65,894,000 | +82.2% | 858,781 | +2.2% | 0.02% | +50.0% |
| Q3 2020 | $36,173,000 | -10.3% | 840,069 | -10.0% | 0.01% | -16.7% |
| Q2 2020 | $40,316,000 | +34.2% | 933,456 | -10.6% | 0.01% | +9.1% |
| Q1 2020 | $30,041,000 | -54.6% | 1,044,194 | 0.0% | 0.01% | -38.9% |
| Q4 2019 | $66,233,000 | +382.9% | 1,044,194 | +114.6% | 0.02% | +350.0% |
| Q3 2019 | $13,715,000 | – | 486,682 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Western Financial Corp/CA | 820,320 | $33,272,179 | 21.56% |
| Aquilo Capital Management, LLC | 1,103,515 | $44,758,568 | 16.81% |
| M28 Capital Management LP | 143,900 | $5,836,584 | 5.56% |
| WEALTH EFFECTS LLC | 155,620 | $6,311,951 | 3.60% |
| Evolutionary Tree Capital Management, LLC | 92,095 | $3,735,373 | 3.59% |
| Privium Fund Management B.V. | 221,015 | $8,867,122 | 3.36% |
| JOHNSON & JOHNSON | 247,598 | $10,043 | 2.92% |
| COMMODORE CAPITAL LP | 462,111 | $18,743 | 2.82% |
| Avidity Partners Management LP | 1,375,000 | $55,770,000 | 1.21% |
| Capital Impact Advisors, LLC | 26,853 | $1,089,158 | 1.06% |